Cansu Yol
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Cansu Yol has a total of 52 co-authors. Here are the top co-authors by number of shared publications:
- Akif Turna
Department of Thoracic Surgery, Cerrahpasa Medical Faculty, İstanbul University-Cerrahpasa, Istanbul, Turkey
1 shared publication - Ali İhSan Anadolulu
Istanbul Medeniyet University, Turkey
1 shared publication Alicia Latham
Clinical Genetics Service, Department of Medicine, Memorial Sloan Kettering Cancer Center , New York, NY
1 shared publication- Alvin C. Goh
Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA
1 shared publication - Andrew T. Lenis
Columbia University, New York, New York
1 shared publication - Ayşim Büge Öz
Department of Pathology, Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, 34098 Istanbul, Türkiye
1 shared publication
Latest Publications
- Open Access
- 16 July 2026
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
Comprehensive clinical and genomic analysis of early-onset cancer of the bladder and upper urinary tract
Background: Urothelial cancer typically affects older adults, yet early-onset urothelial cancer (age 45 years and younger) cases are rising and remain poorly characterized. We hypothesized that early-onset urothelial cancer exhibits distinct clinical and genomic features that reflect a different biological etiology from standard-onset urothelial cancer. Methods: We compared clinical, pathologic, and genomic characteristics of patients with early-onset urothelial cancer vs standard-onset urothelial cancer evaluated at Memorial Sloan Kettering Cancer Center from 2000 through 2024. Clinical data included 9221 patients, with tumor and germline genomic profiling by Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT) assay in 2753 patients. Results: Early-onset urothelial cancer accounted for 335 of 9221 (3.6%) patients. Early-onset urothelial cancer patients were more likely never-smokers (43% vs 26%, P < .001), female (30% vs 25%, P = .034), and of Asian race (7.4% vs 3.1%, P < .001). Early-onset urothelial cancer tumors were more often low-grade (41% vs 23%, P < .001) and of pure nonurothelial histology (4.0% vs 1.7%, P = .003). Early-onset urothelial cancer showed marked enrichment for HRAS mutations, independent of histologic subtype, and HRAS-mutated tumors had reduced APOBEC-associated mutation signatures. Germline pathogenic variants were detected in 21.0% of early-onset vs 17.2% of standard-onset urothelial cancer patients (P = .43), driven mostly by mismatch repair and MUTYH gene alterations. Rare cases of somatic mosaicism in HRAS and ERCC2 were observed in patients with very early-onset disease. Conclusions: Early-onset urothelial cancer represents a biologically distinct subset characterized by HRAS-driven oncogenesis, reduced APOBEC mutagenesis, frequent germline variants, and, rarely, somatic mosaicism. These findings suggest developmental or genetic mechanisms underlying early-onset urothelial cancer and supporting age- and biology-informed approaches to risk assessment, genetic counseling, and targeted therapy development.
- 16 July 2026
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
Open AccessComprehensive clinical and genomic analysis of early-onset cancer of the bladder and upper urinary tract
Background: Urothelial cancer typically affects older adults, yet early-onset urothelial cancer (age 45 years and younger) cases are rising and remain poorly characterized. We hypothesized that early-onset urothelial cancer exhibits distinct clinical and genomic features that reflect a different biological etiology from standard-onset urothelial cancer. Methods: We compared clinical, pathologic, and genomic characteristics of patients with early-onset urothelial cancer vs standard-onset urothelial cancer evaluated at Memorial Sloan Kettering Cancer Center from 2000 through 2024. Clinical data included 9221 patients, with tumor and germline genomic profiling by Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT) assay in 2753 patients. Results: Early-onset urothelial cancer accounted for 335 of 9221 (3.6%) patients. Early-onset urothelial cancer patients were more likely never-smokers (43% vs 26%, P < .001), female (30% vs 25%, P = .034), and of Asian race (7.4% vs 3.1%, P < .001). Early-onset urothelial cancer tumors were more often low-grade (41% vs 23%, P < .001) and of pure nonurothelial histology (4.0% vs 1.7%, P = .003). Early-onset urothelial cancer showed marked enrichment for HRAS mutations, independent of histologic subtype, and HRAS-mutated tumors had reduced APOBEC-associated mutation signatures. Germline pathogenic variants were detected in 21.0% of early-onset vs 17.2% of standard-onset urothelial cancer patients (P = .43), driven mostly by mismatch repair and MUTYH gene alterations. Rare cases of somatic mosaicism in HRAS and ERCC2 were observed in patients with very early-onset disease. Conclusions: Early-onset urothelial cancer represents a biologically distinct subset characterized by HRAS-driven oncogenesis, reduced APOBEC mutagenesis, frequent germline variants, and, rarely, somatic mosaicism. These findings suggest developmental or genetic mechanisms underlying early-onset urothelial cancer and supporting age- and biology-informed approaches to risk assessment, genetic counseling, and targeted therapy development.
- Open Access
- 20 April 2026
- Published by MDPI AG in International Journal of Translational Medicine
- Vol. 6 (2) , 17
CD34-Stained Microvessel Density and Immune Checkpoint Inhibitor Outcomes in Metastatic Non-Squamous Non-Small Cell Lung Cancer: A Retrospective Study
Background/Objectives: Immune checkpoint inhibitors (ICIs) improve outcomes in metastatic non-squamous non-small cell lung cancer (NSCLC), yet predictive biomarkers remain limited. This study investigated whether CD34-stained microvessel density (MVD) is associated with ICI efficacy. Methods: Patients with metastatic non-squamous NSCLC and tumor specimen suitable for anti-CD34 immunohistochemistry were included. In the derivation cohort, ROC analysis for objective response rate (ORR; CR + PR) identified a Youden-optimized threshold of 14.5 vessels/HPF (×400) (sensitivity 67%, specificity 93%; AUC 0.744, 95% CI 0.53–0.95; p = 0.021), which was applied without re-optimization to an internal validation cohort and a chemotherapy-only comparator. Results: In the derivation cohort, (n = 25), ORR was higher with MVD ≥ 14.5 than p = 0.004) and OS/TFST were longer (OS: 53.0 vs. 17.1 months, p = 0.037; TFST: 50.0 vs. 6.0 months, p = 0.014). In the validation cohort (n = 13), MVD ≥ 14.5 was associated with longer TFST (9.0 vs. 4.0 months; p = 0.035) and numerically longer OS (12.0 vs. 7.0 months; p = 0.059). As a cut-off-independent sensitivity analysis, continuous MVD (per five vessels/HPF) was associated with longer TFST (HR 0.663, 95% CI 0.454–0.969; p = 0.034). No association was observed in the chemotherapy-only cohort. Conclusions: Higher CD34-MVD may be a feasible vascular metric associated with ICI outcomes that warrants prospective validation.
- 20 April 2026
- Published by MDPI AG in International Journal of Translational Medicine
- Vol. 6 (2) , 17
Open AccessCD34-Stained Microvessel Density and Immune Checkpoint Inhibitor Outcomes in Metastatic Non-Squamous Non-Small Cell Lung Cancer: A Retrospective Study
Background/Objectives: Immune checkpoint inhibitors (ICIs) improve outcomes in metastatic non-squamous non-small cell lung cancer (NSCLC), yet predictive biomarkers remain limited. This study investigated whether CD34-stained microvessel density (MVD) is associated with ICI efficacy. Methods: Patients with metastatic non-squamous NSCLC and tumor specimen suitable for anti-CD34 immunohistochemistry were included. In the derivation cohort, ROC analysis for objective response rate (ORR; CR + PR) identified a Youden-optimized threshold of 14.5 vessels/HPF (×400) (sensitivity 67%, specificity 93%; AUC 0.744, 95% CI 0.53–0.95; p = 0.021), which was applied without re-optimization to an internal validation cohort and a chemotherapy-only comparator. Results: In the derivation cohort, (n = 25), ORR was higher with MVD ≥ 14.5 than p = 0.004) and OS/TFST were longer (OS: 53.0 vs. 17.1 months, p = 0.037; TFST: 50.0 vs. 6.0 months, p = 0.014). In the validation cohort (n = 13), MVD ≥ 14.5 was associated with longer TFST (9.0 vs. 4.0 months; p = 0.035) and numerically longer OS (12.0 vs. 7.0 months; p = 0.059). As a cut-off-independent sensitivity analysis, continuous MVD (per five vessels/HPF) was associated with longer TFST (HR 0.663, 95% CI 0.454–0.969; p = 0.034). No association was observed in the chemotherapy-only cohort. Conclusions: Higher CD34-MVD may be a feasible vascular metric associated with ICI outcomes that warrants prospective validation.
- Open Access
- 27 March 2024
- Published by Türkiye Çocuk Cerrahisi Dernegi in Turkish Journal of Pediatric Surgery
- Vol. 38 (1) , 7-12
Enterobius vermicularis: A cause or an incidental finding in pediatric appendicitis?
Objectives: This study aimed to investigate the incidence of Enterobius vermicularis (E. vermicularis) in appendectomy specimens and its contribution to the pathogenesis of appendicitis. Patients and methods: The files of appendectomy specimens from patients who had E. vermicularis between June 2016 and June 2022 were reviewed retrospectively. The samples of patients whose appendectomy specimens showed E. vermicularis were analyzed in three groups according to the results of histopathological evaluation: reactive lymphoid hyperplasia, acute appendicitis, and perforated appendicitis. Results: The files of 1,334 patients were examined, and E. vermicularis was found histopathological in 24 (1.8%) patients (15 males, 9 females; mean age: 11.2±2.9 years; range, 7 to 17 years). Histopathological examination of appendectomy specimens revealed reactive lymphoid hyperplasia in 15, acute appendicitis in six, and perforated appendicitis in three. Only neutrophil counts were significantly different in patients with reactive lymphoid hyperplasia and acute appendicitis (pConclusion: The high rate of histopathological reactive lymph nodes in appendectomy specimens with E. vermicularis suggests that this parasite is found incidentally in the appendix. Differentiating enterobiasis from true appendicitis may prevent unnecessary appendectomies.
- 27 March 2024
- Published by Türkiye Çocuk Cerrahisi Dernegi in Turkish Journal of Pediatric Surgery
- Vol. 38 (1) , 7-12
Open AccessEnterobius vermicularis: A cause or an incidental finding in pediatric appendicitis?
Objectives: This study aimed to investigate the incidence of Enterobius vermicularis (E. vermicularis) in appendectomy specimens and its contribution to the pathogenesis of appendicitis. Patients and methods: The files of appendectomy specimens from patients who had E. vermicularis between June 2016 and June 2022 were reviewed retrospectively. The samples of patients whose appendectomy specimens showed E. vermicularis were analyzed in three groups according to the results of histopathological evaluation: reactive lymphoid hyperplasia, acute appendicitis, and perforated appendicitis. Results: The files of 1,334 patients were examined, and E. vermicularis was found histopathological in 24 (1.8%) patients (15 males, 9 females; mean age: 11.2±2.9 years; range, 7 to 17 years). Histopathological examination of appendectomy specimens revealed reactive lymphoid hyperplasia in 15, acute appendicitis in six, and perforated appendicitis in three. Only neutrophil counts were significantly different in patients with reactive lymphoid hyperplasia and acute appendicitis (pConclusion: The high rate of histopathological reactive lymph nodes in appendectomy specimens with E. vermicularis suggests that this parasite is found incidentally in the appendix. Differentiating enterobiasis from true appendicitis may prevent unnecessary appendectomies.
- Open Access
- 30 June 2022
- Published by Association of Basic Medical Sciences of FBIH in Biomolecules and Biomedicine
- Vol. 22 (6) , 894-900
Relationship between PD-L1 expression and prognostic factors in high-risk cutaneous squamous and basal cell carcinoma
This study aimed to investigate the programmed cell death-ligand 1 (PD-L1) expression in cutaneous squamous cell carcinoma (cSCC) and basal cell carcinoma (BCC) and its relationship with prognostic factors in tumors that are not in the head and neck region and are therefore relatively less exposed to the sun. This retrospective cross-sectional study included 25 invasive cSCC and 42 BCC cases with a diameter ≥ 2 cm located outside the head and neck region from 2010 to 2018. The biopsy samples were examined based on the membranous PD-L1 (22C3 clone) staining. Staining results were scored as follows: 0, no staining (negative); 1, < 10% PD-L1 positivity of tumor cells; and 2, ≥ 10% PD-L1 positivity of tumor cells. PD-L1 positivity was not seen in any BCC cases, whereas 11 (44%) of cSCC cases were PD-L1 positive. No significant relationship was observed between PD-L1 expression and prognostic parameters, including tumor diameter, tumor depth, and lymphovascular or perineural invasion in the cSCC group. PD-L1 expression was not associated with prognostic factors in the early stages of BCC and SCC located outside the head and neck region. Therefore, investigating the PD-L1 expression seems to be more relevant in patients with advanced-stage disease.
- 30 June 2022
- Published by Association of Basic Medical Sciences of FBIH in Biomolecules and Biomedicine
- Vol. 22 (6) , 894-900
Open AccessRelationship between PD-L1 expression and prognostic factors in high-risk cutaneous squamous and basal cell carcinoma
This study aimed to investigate the programmed cell death-ligand 1 (PD-L1) expression in cutaneous squamous cell carcinoma (cSCC) and basal cell carcinoma (BCC) and its relationship with prognostic factors in tumors that are not in the head and neck region and are therefore relatively less exposed to the sun. This retrospective cross-sectional study included 25 invasive cSCC and 42 BCC cases with a diameter ≥ 2 cm located outside the head and neck region from 2010 to 2018. The biopsy samples were examined based on the membranous PD-L1 (22C3 clone) staining. Staining results were scored as follows: 0, no staining (negative); 1, < 10% PD-L1 positivity of tumor cells; and 2, ≥ 10% PD-L1 positivity of tumor cells. PD-L1 positivity was not seen in any BCC cases, whereas 11 (44%) of cSCC cases were PD-L1 positive. No significant relationship was observed between PD-L1 expression and prognostic parameters, including tumor diameter, tumor depth, and lymphovascular or perineural invasion in the cSCC group. PD-L1 expression was not associated with prognostic factors in the early stages of BCC and SCC located outside the head and neck region. Therefore, investigating the PD-L1 expression seems to be more relevant in patients with advanced-stage disease.